AbCellera presents new data on two T-cell engager programs

AbCellera presented new data on its T-cell engager programs in two poster presentations at the Society for Immunotherapy of Cancer, or SITC, 38th Annual Meeting. “The data illustrate how AbCellera is leveraging its TCE platform to discover and develop immuno-oncology therapeutics for multiple tumor targets,” the company stated. Bo Barnhart, Ph.D., VP of Translational Research at AbCellera, said: “Altering the affinity of either a small set of CD3-binding antibodies, or an antibody such as SP34-2, is a frequently used strategy to reduce risk of cytokine release syndrome by TCEs. However, we have demonstrated that CD3 affinity alone is not sufficient to optimize TCE function. By pairing functionally diverse CD3-binders with a wide range of tumor-binding arms, our TCE platform has identified promising bispecific molecules.” Neil Aubuchon, Chief Commercial Officer at AbCellera, added: “Since launching our TCE platform in 2021, we’ve gained a deeper understanding of TCE biology that we believe will enable us to rapidly bring best-in-class molecules to the clinic. We look forward to applying these lessons to targets as we work towards bringing better cancer treatments to patients faster.”